1. Steinbrook R. Testing medications in children. N Engl J Med 2002; 347: 1462–70.
2. Kearns GL, Abdel-Rahman SM, Alander SW et al. Developmental pharmacology
– drug disposition, action, and therapy in infants and children. N Engl J Med 2003; 349: 1157–67.
3. Simons FER. Advances in H1-antihistamines. N Engl J Med 2004; 351: 2203–17.
4. Simons FER. H1-antihistamines in children. In: Simons FER, ed. Histamine
and H1-Antihistamines in Allergic Disease, 2nd edn. New York, N.Y.: Marcel
Dekker, Inc., 2002; 437–64.
5. Simons FER, on behalf of the ETAC Study Group. Prospective, long-term
safety evaluation of the H1-receptor antagonist cetirizine in very young children
with atopic dermatitis. J Allergy Clin Immunol 1999; 104: 433–40.
6. Grimfeld A, Holgate ST, Canonica GW et al. Prophylactic management of
children at risk for recurrent upper respiratory infections: the Preventia I
Study. Clin Exp Allergy 2004; 34: 1665–72.
7. Jangi S-M, Asumendi A, Arlucea J et al. Apoptosis of human T-cell acute lymphoblastic
leukemia cells by diphenhydramine, an H1 histamine receptor
antagonist. Oncol Res 2004; 14: 363–72.
8. Malaviya R, Uckun FM. Histamine as an autocrine regulator of leukemic
cell proliferation. Leuk Lymphoma 2000; 36: 367–73.
9. Mann RD, Pearce GL, Dunn N, Shakir S. Sedation with _non-sedating_
antihistamines: four prescriptionevent monitoring studies in general practice.
Br Med J 2000; 320: 1184–7.
10. Finkle WD, Adams JL, Greenland S, Melmon KL. Increased risk of serious
injury following an initial prescription for diphenhydramine. Ann Allergy
Asthma Immunol 2002; 89: 244–50.
11. Simons FER, on behalf of the ETAC study group Population pharmacokinetics
of levocetirizine in very young children: the pediatricians_ perspective.
Pediatr Allergy Immunol 2005; 16: 97–103.
12. Hussein Z, Pitsiu M, Majid O, et al. Retrospective population pharmacokinetics
of levocetirizine in atopic children receiving cetirizine: the ETAC study.
Br J Clin Pharmacol 2005; 59: 28–37.
13. Cranswick N, Turzikova J, Fuchs M, Hulhoven R. Levocetirizine in 1–2
year old children: pharmacokinetic and pharmacodynamic profile. Int J Clin
PharmacolTher 2005; 43: 172–7.
14. Simons FER, Simons KJ. Levocetirizine: pharmacokinetics and pharmacodynamics
in children age 6 to11 years. J Allergy Clin Immunol 2005; 116:
355–61.
15. Simons KJ, Benedetti MS, Simons FER, Gillard M, Baltes E. Relevance of H1-
receptor occupancy to H1-antihistamine dosing in children. J Allergy Clin
Immunol 2007; 119.
16. Wyngaarden JB, Seevers MH. The toxic effects of antihistaminic drugs.
JAMA 1951; 145: 277–82.
17. Baker AM, Johnson DG, Levisky JA et al. Fatal diphenhydramine intoxication
in infants. J Forensic Sci 2003; 48: 425–8.
18. Jumbelic MI, Hanzlick R, Cohle S. Alkylamine antihistamine toxicity and
review of pediatric toxicology registry of the National Association of Medical
Examiners. Am J Forensic Med Pathol 1997; 18: 65–9.
19. Nine JS, Rund CR. Fatality from diphenhydramine monointoxication: a
case report and review of the infant, pediatric, and adult literature. Am J
Forensic Med Pathol 2006; 27: 36–41.
20. Scharman EJ, Erdman AR, Wax PM et al. Diphenhydramine and dimenhydrinate
poisoning: an evidence-based consensus guideline for out-of-hospital
management. Clin Toxicol (Phila) 2006; 44: 205–23.
21. Yamashita Y, Isagai T, Seki Y et al. West syndrome associated with administration
of a histamine H1 antagonist, oxatomide. Kurume Med J 2004; 51:
273–5.
22. Starke PR, Weaver J, Chowdhury BA. Boxed warning added to promethazine
labeling for pediatric use. N Engl J Med 2005; 352: 2653.
23. Owens JA, Rosen CL, Mindell JA. Medication use in the treatment of pediatric
insomnia: results of a survey of community-based pediatricians. Pediatrics
2003; 111: e628–35.
24. Leelataweedwud P, Vann Jr WF. Adverse events and outcomes of conscious
sedation for pediatric patients: study of an oral sedation regimen. J Am
Dent Assoc 2001; 132: 1531–9.
25. Merenstein D, Diener-West M, Halbower AC, Krist A, Rubin HR. The trial of
infant response to diphenhydramine: the TIRED study – a randomized, controlled,
patient-oriented trial. Arch Pediatr Adolesc Med 2006; 160: 707–12.
26. Daviss WB, Scott J. A chart review of cyproheptadine for stimulantinduced
weight loss. J Child Adolesc Psychopharmacol 2004; 14: 65–73.
27. Allotey P, Reidpath DD, Elisha D. Social medication and the control of children:
a qualitative study ofover-the-counter medication among Australian
children. Pediatrics 2004; 114: e378–83.
28. Simons FER, Silas P, Portnoy JM, Catuogno J, Chapman D, Olufade AO.
Safety of cetirizine in infants 6 to 11 months of age: a randomized, doubleblind,
placebo-controlled trial. J Allergy Clin Immunol 2003; 111: 1244–8.
29. Stevenson J, Cornah D, Evrard P et al. Long-term evaluation of the impact
of the H1-receptor antagonist cetirizine on the behavioral, cognitive and psychomotor
development of very young children with atopic dermatitis. Pediatr
Res 2002; 52: 251–7.
30. Ridout SM, Tariq SM. Cetirizine overdose in a young child. J Allergy Clin
Immunol 1997; 99: 860–1.
31. Cobb DB, Watson WA, Fernandez MC. High-dose loratadine exposure in a
six-year-old child. Vet Hum Toxicol 2001; 43: 163–4.